Immune-mediated muscle and skin inflammation in dogs (Polymyositis and Dermatomyositis)

  • Occurrence: common
  • Location of disease: General/Whole body
Author: Dr. med. vet. Gisa Löwe | Last modified: 08.08.2026
Open table of contents

When to visit the vet?

Non-urgent see a veterinarian within 2–3 days

?

If the condition worsens / symptoms persist, consult a veterinarian.

Download/Print

Definition

Polymyositis and dermatomyositis are inflammatory conditions in dogs characterized by generalized inflammation of the muscles and, in some cases, the skin. They lead to muscle weakness and skin changes.

The most important facts at a glance

Polymyositis and dermatomyositis are rare, autoimmune muscle diseases in dogs where the immune system attacks muscle cells. Dog breeds such as Collies and Shetland Sheepdogs are particularly affected, with genetic factors playing a role. Environmental factors and infections could also act as triggers. A dysregulation of immune cells, especially T-lymphocytes, leads to inflammation in the muscles.

Symptoms include a stiff gait, muscle swelling, weakness, and pain. In some cases, an enlarged esophagus, skin lesions, and weight loss may occur. Diagnosis requires a thorough examination by a veterinarian, including muscle and skin biopsies as well as blood tests. Elevated levels of muscle enzymes such as creatine kinase can indicate muscle damage. Imaging techniques such as ultrasound or MRI help to assess the condition of the muscle.

Treatment aims to reduce inflammation and control symptoms. Glucocorticoids such as prednisone are frequently used. If necessary, additional immunosuppressive medications are used. Physiotherapy and an adapted diet support the treatment. The prognosis varies depending on the severity and response to therapy. With early diagnosis, quality of life can be improved; however, some dogs may experience permanent limitations.

There are no specific preventive measures, as the exact causes are unclear. Responsible breeding can reduce the risk in genetically predisposed breeds. Early signs should be taken seriously and clarified by a veterinarian. Regular health checks are important to detect problems early.

Causes

Polymyositis and dermatomyositis belong to the autoimmune myopathies, in which the dog’s immune system attacks its own muscle cells. These conditions are rare but can occur more frequently in certain dog breeds.

The exact cause of these conditions is not yet fully understood. Genetic predispositions play a role, particularly in breeds such as the Collie and Shetland Sheepdog. Environmental factors and infections could also be potential triggers. The genetic background suggests that certain genes could increase susceptibility to these autoimmune reactions.

Some studies suggest that a dysregulation of certain immune cells, particularly T-lymphocytes, leads to an overreaction of the immune system. These cells mistakenly attack muscle tissue, leading to inflammation and the characteristic symptoms of the conditions.

Symptoms

Rare symptoms:

The symptoms of polymyositis and dermatomyositis in dogs can vary depending on which tissues are affected and how severe the inflammation is. Frequently, affected dogs show a creeping muscle weakness, which is initially noticeable during physical exertion.

Another common symptom is muscle stiffness, which occurs particularly after rest periods or in the morning after waking up. In severe cases, muscle atrophy, i.e., the loss of muscle mass, can occur.

In dermatomyositis, additional skin changes occur, which can appear as red, scaly, or crusty lesions on the face, ear tips, or other parts of the body. These skin changes are often associated with itching.

Therapy

The treatment of polymyositis and dermatomyositis aims to reduce inflammation and control symptoms. Glucocorticoids such as prednisone are frequently used to suppress the immune system and reduce inflammation.

In some cases, additional immunosuppressive medications may be necessary to keep the disease under control. Medications such as azathioprine or cyclophosphamide are sometimes used when steroids alone are not sufficient.

In addition to drug therapy, physiotherapy treatment can be helpful to maintain muscle strength and improve mobility. An adapted diet and regular but moderate exercise are also important.

Prognosis and follow-up care

The prognosis for dogs with polymyositis and dermatomyositis varies depending on the severity of the disease and the response to treatment. With early diagnosis and consistent therapy, quality of life can be significantly improved and symptoms controlled.

Some dogs respond well to treatment and can lead a relatively normal life, while others may have permanent limitations due to muscle atrophy or recurring inflammatory episodes.

Regular veterinary check-ups are important to monitor the course of the disease and adjust the therapy if necessary.

Prevention

Since the exact causes of polymyositis and dermatomyositis are not fully understood, there are no specific preventive measures. With known genetic predispositions in certain breeds, responsible breeding can help reduce the risk.

Early diagnosis and treatment are crucial to have the best chance of successful management. Dog owners should watch for early signs of muscle weakness or skin changes and consult a veterinarian immediately if a condition is suspected.

Regular health checks can help to identify potential problems early and, if necessary, take preventive measures.

Outlook on current research

*]:pointer-events-auto scroll-mt-[calc(var(–header-height)+min(200px,max(70px,20svh)))]” dir=”auto” data-turn-id=”request-69e25e16-a06c-83eb-81c7-b2046a680748-11″ data-testid=”conversation-turn-58″ data-scroll-anchor=”true” data-turn=”assistant”>

Polymyositis and dermatomyositis belong to the idiopathic inflammatory myopathies, i.e., autoimmune muscle diseases. In dermatomyositis, typical skin involvement is also present. The most important research outlook today is that these diseases are no longer understood as uniform disorders, but as biologically distinct subgroups. In particular, the classic diagnosis of polymyositis is now made much more critically than in the past. (pubmed.ncbi.nlm.nih.gov, lancet.com)

A central field of research is more precise classification. Myositis-specific autoantibodies, MRI, muscle biopsy, and increasingly ultrasound play an important role. The goal is to recognize forms of the disease earlier, better predict the course and organ involvement, and adapt therapy more individually. Especially in dermatomyositis, intensive research is being conducted on the underlying signaling pathways, such as interferon-mediated inflammation and complement activation. (lancet.com, pubmed.ncbi.nlm.nih.gov)

Therapeutically, research is shifting from non-specific immunosuppression toward targeted therapies. JAK inhibitors, biologics, and other more precise immunomodulatory approaches are being investigated, particularly in severe or therapy-resistant cases. (pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov)

Overall, the outlook is good: research is clearly moving toward serology- and biomarker-based precision medicine with better diagnostics and more targeted treatment.

Frequently Asked Questions (FAQs)

1. What are polymyositis and dermatomyositis?
Polymyositis is an inflammatory disease of the skeletal muscles, while dermatomyositis describes a combined inflammatory disease of the skin and muscles. Both are considered immune-mediated diseases in which the immune system attacks the body's own tissue.
2. Which breeds are particularly affected?
Juvenile dermatomyositis is a hereditary disease in Collies and Shetland Sheepdogs that appears as early as puppyhood. Polymyositis occurs in many breeds, but more frequently in Boxers, Newfoundlands, German Shepherds, and middle-aged to older Retrievers.
3. What symptoms do affected dogs show?
Symptoms of polymyositis include muscle weakness, a stiff gait, rapid fatigue, muscle pain, and often a swallowing disorder due to involvement of the esophageal muscles. In dermatomyositis, skin changes with alopecia, scales, erosions, and scar tissue formation on the head, paws, and tail are also present.
4. How is the diagnosis made?
Indicative findings are significantly elevated muscle enzymes (CK, AST) in the blood. Electromyography shows typical pathological spontaneous activity. The definitive diagnosis is made by a muscle biopsy with histological and immunohistochemical examination. In dermatomyositis, a skin biopsy is also taken.
5. What role does esophageal involvement play?
In polymyositis, the muscles of the esophagus are frequently affected, which can lead to regurgitation and aspiration pneumonia. A megaesophagus is a dreaded complication and should be ruled out by contrast X-ray in every suspected case, as it significantly influences the prognosis.
6. How are the diseases treated?
Therapy consists of immunosuppressants, usually high-dose prednisolone, often combined with azathioprine, cyclosporine, or mycophenolate. In dermatomyositis, pentoxifylline is also used to treat skin inflammation. Treatment usually lasts several months, sometimes lifelong at a low maintenance dose.
7. Can recurrences occur?
Yes, recurrences are common, especially after a dose reduction that is too rapid. A slow, controlled reduction of immunosuppression over months is therefore important. Some dogs require permanent low-dose maintenance therapy.
8. What is the prognosis?
The prognosis is highly variable. Mild cases of juvenile dermatomyositis respond well to therapy, and the changes often partially regress. Polymyositis with megaesophagus has a significantly poorer prognosis, as aspiration pneumonia can become life-threatening.
9. What is the relevance for breeding?
Juvenile dermatomyositis in Collies and Shetland Sheepdogs is hereditary. Genetic tests or risk analyses are established for some lines. Affected dogs and carriers should be removed from breeding. In other breeds, the genetic component is less clear.
10. How does the disease differ from muscular dystrophy?
Muscular dystrophies are non-inflammatory, genetic muscle diseases with progressive muscle wasting. They do not respond to immunosuppression. In contrast, polymyositis and dermatomyositis show inflammatory infiltrates in the biopsy and respond to immunosuppression.

Literature

  • Evans, J., Levesque, D., & Shelton, G. D. (2004). Canine inflammatory myopathies: A clinicopathologic review of 200 cases. Journal of Veterinary Internal Medicine, 18(5), 679–691. https://doi.org/10.1892/0891-6640(2004)182.0.CO;2
  • Tauro, A., Addicott, D., Foale, R. D., Bowman, C., Hahn, C., Long, S., Massey, J., Haley, A. C., Knowler, S. P., Day, M. J., Kennedy, L. J., & Rusbridge, C. (2015). Clinical features of idiopathic inflammatory polymyopathy in the Hungarian Vizsla. BMC Veterinary Research, 11, 97. https://doi.org/10.1186/s12917-015-0408-7
  • Han, J., Jang, K., Cho, S. B., Kim, S., Oh, S., & Kim, H. J. (2024). Successful diagnosis and treatment of canine polymyositis: Utilizing MRI and immunohistochemistry for accurate detection. BMC Veterinary Research, 20(1), 560. https://doi.org/10.1186/s12917-024-04356-6
  • Platt, S. R., McConnell, J. F., Garosi, L. S., Ladlow, J., de Stefani, A., & Shelton, G. D. (2006). Magnetic resonance imaging in the diagnosis of canine inflammatory myopathies in three dogs. Veterinary Radiology & Ultrasound, 47(6), 532–537. https://doi.org/10.1111/j.1740-8261.2006.00181.x
  • Baiker, K., Scurrell, E., Wagner, T., Walker, D., Solano-Gallego, L., Holt, E., Smyth, B., Summers, B. A., & Schöniger, S. (2011). Polymyositis following Vogt-Koyanagi-Harada-like syndrome in a Jack Russell terrier. Journal of Comparative Pathology, 144(4), 317–323. https://doi.org/10.1016/j.jcpa.2010.10.006
  • Ito, D., Okada, M., Jeffery, N. D., Kitagawa, M., Uchida, K., & Watari, T. (2009). Symptomatic tongue atrophy due to atypical polymyositis in a Pembroke Welsh Corgi. Journal of Veterinary Medical Science, 71(8), 1063–1067. https://doi.org/10.1292/jvms.71.1063
  • Clark, L. A., Credille, K. M., Murphy, K. E., & Rees, C. A. (2005). Linkage of dermatomyositis in the Shetland Sheepdog to chromosome 35. Veterinary Dermatology, 16(6), 392–394. https://doi.org/10.1111/j.1365-3164.2005.00469.x
  • Rees, C. A., & Boothe, D. M. (2003). Therapeutic response to pentoxifylline and its active metabolites in dogs with familial canine dermatomyositis. Veterinary Therapeutics: Research in Applied Veterinary Medicine, 4(3), 234–241.
  • Hargis, A. M., Haupt, K. H., Hegreberg, G. A., Prieur, D. J., & Moore, M. P. (1984). Familial canine dermatomyositis: Initial characterization of the cutaneous and muscular lesions. The American Journal of Pathology, 116(2), 234–244.